APA (7th ed.) Citation

Zhao, Q., Zhang, J., Xu, L., Yang, H., Liang, N., Zhang, L., . . . Zhang, X. (2021). Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. Frontiers in immunology, 12, 730320. https://doi.org/10.3389/fimmu.2021.730320

Chicago Style (17th ed.) Citation

Zhao, Qing, Jianwei Zhang, Lingyi Xu, Huaxia Yang, Naixin Liang, Li Zhang, Fengchun Zhang, and Xuan Zhang. "Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis." Frontiers in Immunology 12 (2021): 730320. https://doi.org/10.3389/fimmu.2021.730320.

MLA (9th ed.) Citation

Zhao, Qing, et al. "Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis." Frontiers in Immunology, vol. 12, 2021, p. 730320, https://doi.org/10.3389/fimmu.2021.730320.